AMG 172

Drug Profile

AMG 172

Alternative Names: AMG172

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Amgen
  • Class Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Renal cell carcinoma

Most Recent Events

  • 05 Dec 2012 Phase-I clinical trials in Renal cell carcinoma (second-line therapy or greater) in France (Parenteral) (NCT01497821)
  • 05 Dec 2012 Phase-I clinical trials in Renal cell carcinoma (second-line therapy or greater) in Germany (Parenteral) (NCT01497821)
  • 20 Dec 2011 Phase-I clinical trials in Renal cell carcinoma (second-line therapy or greater) in USA (Parenteral) (NCT01497821)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top